(Total Views: 735)
Posted On: 12/14/2021 9:38:13 AM
Post# of 148878
I am with you Ohm. The talk about buy outs and partners is so short sighted. We have 7 indications in the works right now and on the cusp of approval in 2022. If everyone were proficient at math and actually ran the numbers of just what every indication is worth. Would they still be thinking about a buy out at an offer that will be at best… Pennies on the dollar to our short term potential of only a year? Let alone our potential long term 3-5 years of huge stock value as we might average as many as 4-6 indication approvals annually on our platform MAB.
People should research Truvada to see that they have averaged 6 approvals annually on their MAB and is the biggest platform drug approvals for one drug at almost 40 indication approvals for just one MAB drug in Truvada. If you look to the future and know that we also have that potential… doesn’t it make sense to hold your cards close to your chest and play your hand? We have something special going on here. People are wearing blinders and not seeing this is all I can figure.
It amazes me… by the shear amount of Block Buster indications we have working for us right now. Giving a partnership or a part of our nest eggs of our golden eggs to big Pharma could just kill the goose and I have done enough of that in my life. I am all for short term gains. I define short term as a year from now. I see by the end of 2022 at least half or much more of our indications we are working on currently getting approval and stock value being huge and probably over $100/share. Then you have a buy out offer at maybe 2 BTDs and a EUA and say an offer of only $50/share in 3rd quarter of 2022. Can most of us wait another 3 months to double our stock value? With the potential to grow annually with a platform drug? The potential in our future is really amazing and to sell before it has a chance to happen is very unwise.
Can people just buy into success? This is what it seems people need immediate gratification of success. Searching for that immediate success. The people talking BO or partnerships must not of done their homework on the potential and stock value of each indication. Some want a bail out of their investment now when the investment could very well grow substantially by the end of 2022 just doesn’t make sense to me. All I can say is break down the market value of each indication currently and add it all up and see what cards your holding. It’s a tough call to throw away what might be the winning hand and missing out. But you just keep talking about buy outs and partnerships. While I look at the big picture and hope people are smarter than that and want to grow into our own big pharmaceutical company. This is where the huge money is. After two approvals will you fold your hand and sell out? Not me… I will always vote to deny both partners and buy outs. I can clearly see the wealth of my decisions. Can you see the big picture?
People should research Truvada to see that they have averaged 6 approvals annually on their MAB and is the biggest platform drug approvals for one drug at almost 40 indication approvals for just one MAB drug in Truvada. If you look to the future and know that we also have that potential… doesn’t it make sense to hold your cards close to your chest and play your hand? We have something special going on here. People are wearing blinders and not seeing this is all I can figure.
It amazes me… by the shear amount of Block Buster indications we have working for us right now. Giving a partnership or a part of our nest eggs of our golden eggs to big Pharma could just kill the goose and I have done enough of that in my life. I am all for short term gains. I define short term as a year from now. I see by the end of 2022 at least half or much more of our indications we are working on currently getting approval and stock value being huge and probably over $100/share. Then you have a buy out offer at maybe 2 BTDs and a EUA and say an offer of only $50/share in 3rd quarter of 2022. Can most of us wait another 3 months to double our stock value? With the potential to grow annually with a platform drug? The potential in our future is really amazing and to sell before it has a chance to happen is very unwise.
Can people just buy into success? This is what it seems people need immediate gratification of success. Searching for that immediate success. The people talking BO or partnerships must not of done their homework on the potential and stock value of each indication. Some want a bail out of their investment now when the investment could very well grow substantially by the end of 2022 just doesn’t make sense to me. All I can say is break down the market value of each indication currently and add it all up and see what cards your holding. It’s a tough call to throw away what might be the winning hand and missing out. But you just keep talking about buy outs and partnerships. While I look at the big picture and hope people are smarter than that and want to grow into our own big pharmaceutical company. This is where the huge money is. After two approvals will you fold your hand and sell out? Not me… I will always vote to deny both partners and buy outs. I can clearly see the wealth of my decisions. Can you see the big picture?
(10)
(0)Scroll down for more posts ▼
